Financial Performance - The company's revenue for Q1 2024 was ¥134,549,472.48, a decrease of 42.34% compared to ¥233,350,600.29 in the same period last year[5] - Net profit attributable to shareholders was ¥8,001,565.58, down 76.32% from ¥33,794,308.43 year-on-year[5] - Basic earnings per share decreased by 77.42% to ¥0.07 from ¥0.31 in the previous year[5] - Total operating revenue for Q1 2024 was CNY 134.55 million, a decrease of 42.4% compared to CNY 233.35 million in the same period last year[20] - Net profit for Q1 2024 was CNY 8.77 million, a decline of 74.0% from CNY 33.81 million in Q1 2023[22] - Earnings per share for Q1 2024 were CNY 0.07, compared to CNY 0.31 in the same quarter last year[22] Cash Flow - The net cash flow from operating activities was ¥14,005,060.14, reflecting a decline of 67.50% compared to ¥43,097,793.56 in Q1 2023[5] - Cash inflow from operating activities was CNY 134.56 million, down 38.3% from CNY 217.94 million in Q1 2023[24] - The total cash outflow from operating activities was ¥120,559,575.85, down from ¥174,837,490.23 in the previous year[25] - The net cash flow from investment activities was ¥78,848,297.85, recovering from a negative cash flow of ¥21,164,979.71 in Q1 2023[25] - The net increase in cash and cash equivalents for Q1 2024 was ¥93,440,251.52, a substantial rise from ¥22,466,667.14 in Q1 2023[25] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥1,660,791,990.90, a decrease of 1.35% from ¥1,683,513,672.39 at the end of the previous year[5] - The company's total liabilities decreased to CNY 275.24 million from CNY 307.15 million year-over-year, a reduction of 10.4%[21] - Total liabilities decreased by 49.20% in short-term borrowings, reflecting a reduction in bank loans[11] - Total equity increased to CNY 1,385.55 million from CNY 1,376.36 million, reflecting a growth of 0.7%[21] Research and Development - The company reported a significant drop in R&D expenses, which were ¥3,672,063.05, down 54.10% from ¥7,999,391.16 in the same period last year[12] - Research and development expenses for Q1 2024 were CNY 3.67 million, a decrease of 54.0% compared to CNY 8.00 million in the previous year[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 8,140[14] - The largest shareholder, Liansheng Chemical Group Co., Ltd., holds 52.78% of shares, totaling 57,000,000 shares[14] Inventory and Receivables - Accounts receivable increased to ¥72,232,662.22 from ¥56,422,428.53, representing a growth of about 28%[18] - Inventory decreased to ¥87,019,265.49 from ¥115,782,015.47, a reduction of approximately 25%[18] Other Financial Activities - The company reported a financial income of CNY 4.23 million, compared to a financial expense of CNY 2.48 million in the same period last year[21] - The company received tax refunds amounting to CNY 7.21 million, slightly down from CNY 8.63 million in Q1 2023[24] - The company is actively exploring new product development and market expansion strategies[15] Audit and Reporting - The company did not undergo an audit for the Q1 2024 report[26] - The report was released by the board of directors on April 26, 2024[26]
联盛化学(301212) - 2024 Q1 - 季度财报